Neurology · Medical Literature
Effects of the Digital App "Support, Monitoring and Reminder Technology for Mild Dementia" (SMART4MD) on People With Mild Cognitive Impairment and Their Informal Caregivers: 18-Month Multicenter Pragmatic Randomized Controlled Trial.
Abstract
Previous research has shown that mobile health (mHealth) interventions are effective in reminding older adults with chronic conditions about health care appointments and promoting adherence to medication schedules. However, the evidence is limited by the short duration and poor quality of the interventions. We evaluated the effectiveness of the Support, Monitoring and Reminder Technology for Mild Dementia (SMART4MD) tablet app in improving the quality of life (QoL) of people with mild cognitive impairment (PwMCI) and their caregivers through medication reminders and health care appointment alerts. An 18-month pragmatic randomized controlled trial was conducted in Spain and Sweden from December 2017 to September 2020 and included 1078 PwMCI and their informal caregivers. For PwMCI, the intervention improved the primary outcome, composite Quality of Life in Alzheimer's Disease (QoL-AD) scale, at 18 months (mean difference 0.75, 95% CI 0.07-1.42; P=.03), and a similar effect was observed at 6 months (mean difference 0.73, 95% CI 0.09-1.36; P=.02). Confirmatory secondary outcomes for PwMCI, including medication adherence (P=.12) and Mini-Mental State Examination (MMSE) score (P=.45), did not differ significantly between groups at the 18-month follow-up. Exploratory analyses showed higher total accumulated quality-adjusted life years (QALYs) at 6 months for PwMCI (mean difference 0.035, 95% CI 0.02-0.05; nominal P<.001), informal caregivers (mean difference 0.050, 95% CI 0.04-0.07; nominal P<.001), and dyads (mean difference 0.085, 95% CI 0.06-0.11; nominal P<.001). A dropout rate of approximately 40% (429/1083, 39.61%) was observed in both the intervention and control groups. The SMART4MD intervention was associated with a modest improvement in PwMCI's QoL as measured by the composite QoL-AD score. Evidence for benefits among informal caregivers and dyads was less consistent and should be interpreted as exploratory. Nominally significant findings for exploratory outcomes should be interpreted with caution, as they were not adjusted for multiplicity. ClinicalTrials.gov NCT03325699; https://clinicaltrials.gov/ct2/show/NCT03325699. RR2-10.2196/13711.
Clinical relevance
This article addresses a critical gap in mHealth evidence for neurodegenerative disease management: the lack of large-scale, long-duration RCTs evaluating digital interventions in people with mild cognitive impairment (PwMCI). With MCI representing a high-risk transitional state toward dementia, scalable digital tools that support quality of life and caregiver wellbeing carry significant public health relevance. Clinicians managing MCI in outpatient neurology or geriatrics settings need robust evidence to guide recommendations for adjunctive digital health tools, particularly as app-based interventions proliferate without adequate trial data.
Key findings
1. The SMART4MD tablet app significantly improved the primary outcome — composite Quality of Life in Alzheimer's Disease (QoL-AD) score — in PwMCI at 18 months (mean difference 0.75, 95% CI 0.07–1.42; P=.03), indicating a statistically significant but modest effect. 2. The QoL-AD benefit was also observed at the 6-month interim assessment (mean difference 0.73, 95% CI 0.09–1.36; P=.02), suggesting early and sustained, though modest, QoL gains. 3. Confirmatory secondary outcomes did not reach significance: medication adherence (P=.12) and MMSE score (P=.45) showed no statistically significant between-group differences at 18 months, failing to demonstrate cognitive or adherence benefits. 4. Exploratory QALY analyses showed nominally higher accumulated QALYs at 6 months for PwMCI (mean difference 0.035, 95% CI 0.02–0.05; P<.001), informal caregivers (mean difference 0.050, 95% CI 0.04–0.07; P<.001), and dyads (mean difference 0.085, 95% CI 0.06–0.11; P<.001); however, these were not adjusted for multiplicity and must be interpreted with caution. 5. A pragmatic multinational RCT design (Spain and Sweden; N=1,078 dyads; December 2017–September 2020) strengthens external validity but a dropout rate of approximately 40% (429/1,083; 39.61%) in both arms raises concern for attrition bias affecting long-term outcome interpretation. 6. Benefits among informal caregivers and dyads were categorized as exploratory and deemed less consistent, limiting conclusions about caregiver-directed efficacy.
Practice implications
Clinicians may consider recommending the SMART4MD app as an adjunctive tool for patients with mild cognitive impairment to support modest quality-of-life gains, while explicitly counseling patients and caregivers that no significant improvements in medication adherence or cognitive function (MMSE) were demonstrated over 18 months. The exploratory QALY findings for caregiver dyads are hypothesis-generating and should not yet drive prescriptive recommendations without confirmatory, multiplicity-adjusted trial data. Given the ~40% dropout rate, patient engagement and digital literacy should be assessed at initiation, and follow-up should include structured check-ins to optimize sustained app utilization in this vulnerable population.